

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/755,826	01/04/2001	Charles W. Pearce	PEARCE 26	5388
47396 75	90 04/13/2006		EXAMINER	
HITT GAINES, PC			CHEN, JACK S J	
AGERE SYSTEMS INC. PO BOX 832570			ART UNIT	PAPER NUMBER
RICHARDSON	·		. 2813	
			DATE MAILED: 04/13/2006	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Autieus Occurrence	09/755,826	755,826 PEARCE, CHARLES W.				
Office Action Summary	Examiner	Art Unit				
	Jack Chen	2813				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet	with the correspondence addres	ss			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUN 6(a). In no event, however, may rill apply and will expire SIX (6) Mo cause the application to become	NICATION.  a reply be timely filed  DNTHS from the mailing date of this commu ABANDONED (35 U.S.C. § 133).	·			
Status						
1) Responsive to communication(s) filed on						
· · · · · · · · · · · · · · · · · · ·	-· action is non-final.	•				
·=	· · · · · · · · · · · · · · · · · · ·					
closed in accordance with the practice under E	·	· •				
Disposition of Claims						
4)⊠ Claim(s) <u>1-20</u> is/are pending in the application.	· ·					
4a) Of the above claim(s) is/are withdraw	n from consideration.					
5) Claim(s) is/are allowed.		•				
6)⊠ Claim(s) <u>1-20</u> is/are rejected.	<i>,</i> ,	·				
7) Claim(s) is/are objected to.		·				
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examiner						
10) The drawing(s) filed on is/are: a) acce	epted or b) objected to	b by the Examiner.				
Applicant may not request that any objection to the c	drawing(s) be held in abey	ance. See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction	on is required if the drawin	g(s) is objected to. See 37 CFR 1	.121(d).			
11) The oath or declaration is objected to by the Exa	aminer. Note the attache	ed Office Action or form PTO-1	52.			
Priority under 35 U.S.C. § 119						
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of:		§ 119(a)-(d) or (f).				
1. ☐ Certified copies of the priority documents						
2. Certified copies of the priority documents		<del></del>				
3. Copies of the certified copies of the priori	•	n received in this National Stag	ge			
application from the International Bureau  * See the attached detailed Office action for a list of	, , , ,	at received				
See the attached detailed Office action for a list t	or the certified copies no	n received.				
·						
Attachment(s)						
1) X Notice of References Cited (PTO-892)		Summary (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)		o(s)/Mail Date Informal Patent Application (PTO-152	)\			
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6) Other: _	· · · · · · · · · · · · · · · · · · ·	·)			

Art Unit: 2813

### **DETAILED ACTION**

In view of the appeal brief filed on March 28, 2004, PROSECUTION IS HEREBY REOPENED. New grounds of rejection are set forth below.

To avoid abandonment of the application, appellant must exercise one of the following two options:

- (1) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37 CFR 1.113 (if this Office action is final); or,
- (2) initiate a new appeal by filing a notice of appeal under 37 CFR 41.31 followed by an appeal brief under 37 CFR 41.37. The previously paid notice of appeal fee and appeal brief fee can be applied to the new appeal. If, however, the appeal fees set forth in 37 CFR 41.20 have been increased since they were previously paid, then appellant must pay the difference between the increased fees and the amount previously paid.

A Supervisory Patent Examiner (SPE) has approved of reopening prosecution by signing below:

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 2800

### Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Page 3

Art Unit: 2813

2. Claims 1-8, 10-18 and 20 are rejected under 35 U.S.C. 102(b) as being anticipated by D'Anna et al., U.S./5,841,166.

Re claim 1, D'Anna et al. disclose a method of manufacturing a laterally diffused metal oxide semiconductor (LDMOS) device, which comprises forming a lightly-doped source/drain region 46 (fig. 3A) with only a first dopant (i.e., Arsenic, col. 2, lines 55-60), the lightly-doped source/drain region located between first and second isolation structures 52/54 etc. (figs. 3A-3B); and creating a gate 58 (fig. 3B) over the lightly-doped source/drain region, see figs. 1A-4 and cols. 1-4 for more details.

Re claim 2, wherein forming includes forming a lightly-doped source/drain region with a first N-type dopant (col. 2, lines 56-60).

Re claim 3, wherein the first N-type dopant has an implant dose ranging from about 1E12 atoms/cm.sup.2 to about 1E13 atoms/cm.sup.2 (i.e., 5E12 col. 2, lines 56-60).

Re claim 4, wherein the first N-type dopant has an implant dose of about 5E12 atoms/cm.sup.2 (i.e., 5E12 col. 2, lines 56-60).

Re claim 5, further including diffusing a second dopant (i.e., boron; col. 3, lines 8-18) at least partially across the lightly-doped source/drain region and under the gate to form a first portion of a channel (fig. 3C).

Re claim 6, wherein diffusing the second dopant includes diffusing a P-type dopant having an implant dose ranging from about 1E13 atoms/cm.sup.2 to about 1E14 atoms/cm.sup.2 (i.e., 1E13; col. 3, lines 8-18).

Re claim 7, wherein diffusing the second dopant includes diffusing a P-type dopant having an implant dose about 100 times higher than an implant dose of the first dopant (in this

Application/Control Number: 09/755,826

Art Unit: 2813

case, the p-type dopant having an implant dose of about 5E14 and the fist dopant of about 5E12, also see col. 2, lines 56-60 and col. 3, lines 8-16).

Re claim 8, further including placing a heavy concentration of the first dopant (i.e., arsenic; col. 3, lines 16-18) in a region adjacent a source side of the gate (fig. 3D), and in the lightly-doped source/drain region adjacent a drain side of the gate (fig. 3D).

Re claim 10, wherein placing includes placing an implant dose of the first dopant ranging from about 1E15 atoms/cm.sup.2 to about 1E16 atoms/cm.sup.2 (i.e., 1E15-1E16; col. 3, lines 16-18).

Re claim 11, D'Anna et al. disclose a method of manufacturing an integrated circuit, comprising: fabricating laterally diffused metal oxide semiconductor (LDMOS) transistors (i.e., col. 1, lines 5-10), including: forming a lightly-doped source/drain region 46 (fig. 3A) with only a first dopant (i.e., Arsenic, col. 2, lines 55-60), the lightly-doped source/drain region located between first and second isolation structures 52/54 etc. (figs. 3A-3B); and creating a gate 58 (fig. 3B) over the lightly-doped source/drain region; depositing interlevel dielectric layers (fig. 3D; col. 3, lines 19-28) over the LDMOS transistors; and creating interconnect structures (i.e., source contact, drain contact etc.) in the interlevel dielectric layers and interconnecting the LDMOS transistors to form an operative-integrated circuit (figs. 3D-4; col. 3, lines 19-55), see figs. 1A-4 and cols. 1-4 for more details.

Re claim 12, wherein forming includes forming a lightly-doped source/drain region with a first N-type dopant (col. 2, lines 56-60).

Re claim 13, wherein the first N-type dopant has an implant dose ranging from about 1E12 atoms/cm.sup.2 to about 1E13 atoms/cm.sup.2 (i.e., 5E12 col. 2, lines 56-60).

Application/Control Number: 09/755,826

Art Unit: 2813

Re claim 14, wherein the first N-type dopant has an implant dose of about 5E12 atoms/cm.sup.2 (i.e., 5E12 col. 2, lines 56-60).

Re claim 15, further including diffusing a second dopant (i.e., boron; col. 3, lines 8-18) at least partially across the lightly-doped source/drain region and under the gate to form a first portion of a channel (fig. 3C).

Re claim 16, wherein diffusing the second dopant includes diffusing a P-type dopant having an implant dose ranging from about 1E13 atoms/cm.sup.2 to about 1E14 atoms/cm.sup.2 (i.e., 1E13; col. 3, lines 8-18).

Re claim 17, wherein diffusing the second dopant includes diffusing a P-type dopant having an implant dose about 100 times higher than an implant dose of the first dopant (in this case, the p-type dopant having an implant dose of about 5E14 and the fist dopant of about 5E12, also see col. 2, lines 56-60 and col. 3, lines 8-16).

Re claim 18, further including placing a heavy concentration of the first dopant (i.e., arsenic; col. 3, lines 16-18) in a region adjacent a source side of the gate (fig. 3D), and in the lightly-doped source/drain region adjacent a drain side of the gate (fig. 3D).

Re claim 20, wherein placing includes placing an implant dose of the first dopant ranging from about 1E15 atoms/cm.sup.2 to about 1E16 atoms/cm.sup.2 (i.e., 1E15-1E16; col. 3, lines 16-18).

3. Claims 1-3 and 11-13 are rejected under 35 U.S.C. 102(b) as being anticipated by Kosiak et al., U.S./4,918,026.

Re claim 1, Kosiak et al. disclose a method of manufacturing a laterally diffused metal oxide semiconductor (LDMOS) device, which comprises forming a lightly-doped source/drain

region 114 (figs. 1 and 2B; col. 2, lines 63-66) with only a first dopant (i.e., phosphorous, col. 4, lines 32-39), the lightly-doped source/drain region located between first and second isolation structures 50/120 etc. (fig. 1); and creating a gate 118 (fig. 1) over the lightly-doped source/drain region, see figs. 1-2G and cols. 1-10 for more details.

Re claim 2, wherein forming includes forming a lightly-doped source/drain region with a first N-type dopant (col. 4, lines 32-39; i.e., phosphorus).

Re claim 3, wherein the first N-type dopant has an implant dose ranging from about 1E12 atoms/cm.sup.2 to about 1E13 atoms/cm.sup.2 (i.e., 4.5E12, col. 4, lines 32-39).

Re claim 11, Kosiak et al. disclose a method of manufacturing an integrated circuit, comprising: fabricating laterally diffused metal oxide semiconductor (LDMOS) transistors (also see col. 3, line 63 to col. 4, line 10 regarding transistors), which includes forming a lightly-doped source/drain region 114 (figs. 1 and 2B; col. 2, lines 63-66) with only a first dopant (i.e., phosphorous, col. 4, lines 32-39), the lightly-doped source/drain region located between first and second isolation structures 50/120 etc. (fig. 1); and creating a gate 118 (fig. 1) over the lightly-doped source/drain region; depositing interlevel dielectric layers (i.e., PSG, SOG, etc., col. 7, lines 30-62) over the LDMOS transistors; and creating interconnect structures (i.e., metal contacts, etc., col. 7, lines 30-62) in the interlevel dielectric layers and interconnecting the LDMOS transistors to form an operative-integrated circuit, see figs. 1-2G and cols. 1-10 for more details.

Re claim 12, wherein forming includes forming a lightly-doped source/drain region with a first N-type dopant (col. 4, lines 32-39; i.e., phosphorus).

Application/Control Number: 09/755,826

Art Unit: 2813

Re claim 13, wherein the first N-type dopant has an implant dose ranging from about 1E12 atoms/cm.sup.2 to about 1E13 atoms/cm.sup.2 (i.e., 4.5E12, col. 4, lines 32-39).

## Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. Claims 9 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over D'Anna et al., U.S./5,841,166.

D'Anna et al. disclosed in above, and in particular figs. 3C-4 show that there is distance/space between the drain N+ and the gate. However, D'Anna is silent to the range as recited in the instant claims 9 and 19. With respect to claimed ranges of the distance/space, absent evidence of disclosure of criticality for the range giving unexpected results are considered to involve routine optimization while has been held to be within the level of ordinary skill in the art. As noted in *In re Aller 105 USPQ233*, 255 (CCPA 1955), the selection of reaction parameters such as thickness, distance, temperature and concentration etc. would have been obvious. See also In re Waite 77 USPQ 586 (CCPA 1948); In re Scherl 70 USPQ 204 (CCPA 1946); In re Irmscher 66 USPQ 314 (CCPA 1945); In re Norman 66 USPQ 308 (CCPA 1945); In re Swenson 56 USPQ 372 (CCPA 1942); In re Sola 25 USPQ 433 (CCPA 1935); In re Dreyfus 24 USPQ 52 (CCPA 1934).

Art Unit: 2813

Therefore, the subject matter as a whole would have been obvious to one having ordinary skill in the art at the time the invention was made to select any suitable distance in the method of D'Anna et al. in order to provide normal operation for the MOS under the high voltage. Furthermore, the specification contains no disclosure of either the critical nature of the claimed process/arrangement (i.e. – the claimed ranges of the distance) or any unexpected results arising therefrom. Where patentability is said to be based upon particular chosen limitations or upon another variable recited in a claim, the Applicant must show that the chosen limitations are critical. *In re Woodruff*, 919 F.2d 1575, 1578 (Fed. Cir. 1990).

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jack Chen whose telephone number is (571)272-1689. The examiner can normally be reached on Monday-Friday (9:00am-6:30pm) alternate Monday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Carl W. Whitehead can be reached on (571)272-1702. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 2813

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jack Chen

Primary Examiner Art Unit 2813

April 13, 2006